Lumiracoxib-d6
Modify Date: 2024-01-09 18:18:04
Lumiracoxib-d6 structure
|
Common Name | Lumiracoxib-d6 | ||
|---|---|---|---|---|
| CAS Number | 1225453-72-4 | Molecular Weight | 299.76 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C15H7D6ClFNO2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Lumiracoxib-d6Lumiracoxib-d6 (COX-189-d6) is the deuterium labeled Lumiracoxib. Lumiracoxib is a potent,selective and orally active COX-2 inhibitor with a Ki value of 0.06 μM[1]. Lumiracoxib acts as a nonselective NSAID with anti-inflammatory, analgesic and antipyretic activities. Lumiracoxib can be used for osteoarthritis and bone cancer research[1][2]. |
| Name | Lumiracoxib-d6 |
|---|
| Description | Lumiracoxib-d6 (COX-189-d6) is the deuterium labeled Lumiracoxib. Lumiracoxib is a potent,selective and orally active COX-2 inhibitor with a Ki value of 0.06 μM[1]. Lumiracoxib acts as a nonselective NSAID with anti-inflammatory, analgesic and antipyretic activities. Lumiracoxib can be used for osteoarthritis and bone cancer research[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1]. |
| References |
| Molecular Formula | C15H7D6ClFNO2 |
|---|---|
| Molecular Weight | 299.76 |